MDGL - Madrigal Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
West Conshohocken,
United States
Type: Equity
MDGL price evolution
MDGL
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.92 | $62.05 | $77.2 | $113.31 |
| Short term investments | $534.22 | $170.3 | $221.22 | $216.17 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $637.28 | $235.47 | $301.6 | $331.28 |
| Long term investments | ||||
| Property, plant & equipment | $3.27 | $2.5 | $0.87 | $1.17 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.27 | $2.5 | $0.87 | $1.17 |
| Total investments | $534.22 | $170.3 | $221.22 | $216.17 |
| Total assets | $640.55 | $237.96 | $302.46 | $332.45 |
| Current liabilities | ||||
| Accounts payable | $28.04 | $16.54 | $17.53 | $12.13 |
| Deferred revenue | ||||
| Short long term debt | $0.53 | $0.51 | $0.41 | $0.65 |
| Total current liabilities | $118.55 | $99.67 | $99.71 | $98.35 |
| Long term debt | $116.67 | $116.05 | $99.25 | $83.97 |
| Total noncurrent liabilities | $116.67 | $116.05 | $99.25 | $83.97 |
| Total debt | $117.19 | $116.56 | $99.66 | $84.62 |
| Total liabilities | $235.21 | $215.72 | $198.96 | $182.31 |
| Shareholders' equity | ||||
| Retained earnings | -$1336.29 | -$1224.1 | -$1125.36 | -$1039.56 |
| Other shareholder equity | $0.47 | -$0.04 | -$0.09 | -$0.09 |
| Total shareholder equity | $405.33 | $22.25 | $103.51 | $150.14 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.92 | $331.55 | $36.27 | $54 |
| Short term investments | $534.22 | $27.23 | $234.08 | $230.15 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $637.28 | $361.37 | $271.68 | $285.16 |
| Long term investments | ||||
| Property, plant & equipment | $3.27 | $1.2 | $1.65 | $1.83 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.27 | $1.2 | $1.65 | $1.83 |
| Total investments | $534.22 | $27.23 | $234.08 | $230.15 |
| Total assets | $640.55 | $362.57 | $273.33 | $287 |
| Current liabilities | ||||
| Accounts payable | $28.04 | $23.83 | $21.38 | $1.02 |
| Deferred revenue | ||||
| Short long term debt | $0.53 | $0.6 | $0.41 | $0.32 |
| Total current liabilities | $118.55 | $115.89 | $76.84 | $46.56 |
| Long term debt | $116.67 | $49.29 | $0.39 | $0.47 |
| Total noncurrent liabilities | $116.67 | $49.29 | $0.39 | $0.47 |
| Total debt | $117.19 | $49.89 | $0.8 | $0.79 |
| Total liabilities | $235.21 | $165.18 | $77.22 | $47.02 |
| Shareholders' equity | ||||
| Retained earnings | -$1336.29 | -$962.66 | -$667.31 | -$425.46 |
| Other shareholder equity | $0.47 | -$0.03 | -$0.08 | $0.05 |
| Total shareholder equity | $405.33 | $197.39 | $196.11 | $239.97 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $70.64 | $70.95 | $68.61 | $62.15 |
| Selling, general & administrative | $46.54 | $27.58 | $17.84 | $16.18 |
| Total operating expenses | $117.18 | $98.53 | $86.45 | $78.34 |
| Operating income | -$117.18 | -$98.53 | -$86.45 | -$78.34 |
| Income from continuing operations | ||||
| EBIT | -$108.22 | -$95.24 | -$82.9 | -$74.56 |
| Income tax expense | ||||
| Interest expense | $3.97 | $3.5 | $2.9 | $2.34 |
| Net income | ||||
| Net income | -$112.19 | -$98.74 | -$85.8 | -$76.9 |
| Income (for common shares) | -$112.19 | -$98.74 | -$85.8 | -$76.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $272.35 | $245.44 | $205.16 | $184.81 |
| Selling, general & administrative | $108.15 | $48.13 | $37.32 | $21.86 |
| Total operating expenses | $380.5 | $293.57 | $242.48 | $206.67 |
| Operating income | -$380.5 | -$293.57 | -$242.48 | -$206.67 |
| Income from continuing operations | ||||
| EBIT | -$360.92 | -$291.39 | -$241.85 | -$202.24 |
| Income tax expense | ||||
| Interest expense | $12.71 | $3.96 | ||
| Net income | ||||
| Net income | -$373.63 | -$295.35 | -$241.85 | -$202.24 |
| Income (for common shares) | -$373.63 | -$295.35 | -$241.85 | -$202.24 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$112.19 | -$98.74 | -$85.8 | -$76.9 |
| Operating activities | ||||
| Depreciation | $0.14 | $0.14 | $0.13 | $0.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.85 | $12.66 | $10.97 | $11.25 |
| Total cash flows from operations | -$79.93 | -$84.92 | -$75.31 | -$84.07 |
| Investing activities | ||||
| Capital expenditures | -$1.04 | -$0.34 | -$0.07 | -$0.04 |
| Investments | -$361.09 | $50.54 | -$3.66 | -$186.83 |
| Total cash flows from investing | -$362.12 | $50.2 | -$3.73 | -$186.86 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $479.92 | $4.66 | $28 | $17.9 |
| Net borrowings | $14.93 | $14.93 | $34.79 | |
| Total cash flows from financing | $479.92 | $19.58 | $42.93 | $52.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $37.86 | -$15.14 | -$36.11 | -$218.24 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$373.63 | -$295.35 | -$241.85 | -$202.24 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.47 | $0.41 | $0.47 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $49.73 | $31.63 | $26.87 | $20.73 |
| Total cash flows from operations | -$324.23 | -$224.86 | -$183.92 | -$157.56 |
| Investing activities | ||||
| Capital expenditures | -$1.48 | -$0.22 | -$0.21 | -$0.33 |
| Investments | -$501.04 | $206.9 | -$4.85 | $160.11 |
| Total cash flows from investing | -$502.52 | $206.69 | -$5.05 | $159.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $530.48 | $264.34 | $171.24 | $5.09 |
| Net borrowings | $64.64 | $49.11 | ||
| Total cash flows from financing | $595.12 | $313.45 | $171.24 | $5.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$231.63 | $295.28 | -$17.73 | $7.31 |
News
Fundamentals
| Market cap | $4.21B |
|---|---|
| Enterprise value | $4.23B |
| Shares outstanding | 19.88M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$360.39M |
| EBIT | -$360.92M |
| Net Income | -$373.63M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -11.28 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -11.74 |
| EV/EBIT | -11.72 |
| P/S ratio | N/A |
| P/B ratio | 10.41 |
| Book/Share | 20.37 |
| Cash/Share | 5.03 |
| EPS | -$18.80 |
|---|---|
| ROA | -98.75% |
| ROE | -219.39% |
| Debt/Equity | 0.58 |
|---|---|
| Net debt/EBITDA | -0.38 |
| Current ratio | 5.38 |
| Quick ratio | 5.38 |